Cancer Stem Cells Market Report 2026

Cancer Stem Cells Market Overview

• Cancer Stem Cells market size has reached to $3.24 billion in 2025 • Expected to grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Rising Demand For Personalized Medicine Factor Is Fueling The Growth Of Cancer Stem Cells Market Due To Increasing Focus On Tailored Cancer Treatments • Market Trend: Technological Advancements Innovation In Cancer Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Stem Cells Market?

Cancer stem cells (CSCs) are a small subpopulation of cells within a tumor that possess stem cell–like characteristics, including the ability to self-renew and differentiate into various cell types that make up the bulk of the tumor. They are believed to play a critical role in tumor initiation, growth, metastasis, and recurrence, largely because of their resistance to conventional therapies such as chemotherapy and radiation. The main types of cancer stem cells are solid tumor stem cells, hematopoietic stem cells, breast cancer stem cells, colorectal cancer stem cells, brain cancer stem cells, and leukemia stem cells. In many solid organ cancers, a small population of cancer stem cells sustains tumor growth, exhibits self-renewal, and possesses the ability to regenerate the tumor’s cellular diversity, thereby contributing to treatment resistance and recurrence. The various cancer forms involved are breast, blood, lung, brain, colorectal, pancreatic, bladder, liver, and other cancer forms, which involve the cancerous stem cells (CSCs) and the stem cell-based cancer therapy mode of action. The research types involved are basic research, clinical research, preclinical research, and translational research for pharmaceutical and biotechnology companies, research and academic institutions, hospitals and laboratories, and contract research organizations (CROs).

What Is The Cancer Stem Cells Market Growth Forecast?

The cancer stem cells market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for durable cancer therapies, rising investment in targeted oncology research, expansion of personalized cancer treatment strategies, growing focus on metastasis prevention, increasing integration of csc research in clinical oncology. Major trends in the forecast period include increasing focus on targeting therapy-resistant cancer cells, rising research on csc-specific pathways, growing development of csc biomarkers, expansion of translational and clinical csc research, enhanced integration of csc models in drug discovery.

Global Cancer Stem Cells Market Segmentation

1) By Type: Solid Tumor Stem Cells, Hematopoietic Stem Cells, Breast Cancer Stem Cells, Colorectal Cancer Stem Cells, Brain Cancer Stem Cells, Leukemia Stem Cells 2) By Cancer Forms: Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Other Cancer Forms 3) By Mode Of Action: Targeted Cancerous Stem Cells (Cscs), Stem Cell-Based Cancer Therapy 4) By Research Type: Basic Research, Clinical Research, Preclinical Research, Translational Research 5) By End User: Pharmaceutical And Biotechnology Companies, Research And Academic Institutions, Hospitals And Laboratories, Contract Research Organizations (CROs) Subsegments: 1) By Solid Tumor Stem Cells: Lung Cancer Stem Cells, Liver Cancer Stem Cells, Pancreatic Cancer Stem Cells, Prostate Cancer Stem Cells, Ovarian Cancer Stem Cells 2) By Hematopoietic Stem Cells: Myeloid Stem Cells, Lymphoid Stem Cells, Erythroid Stem Cells, Megakaryocytic Stem Cells, Granulocytic Stem Cells 3) By Breast Cancer Stem Cells: Triple Negative Breast Cancer Stem Cells, Hormone Receptor Positive Breast Cancer Stem Cells, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Stem Cells, Metastatic Breast Cancer Stem Cells, Inflammatory Breast Cancer Stem Cells 4) By Colorectal Cancer Stem Cells: Adenocarcinoma Colorectal Cancer Stem Cells, Mucinous Colorectal Cancer Stem Cells, Signet Ring Cell Colorectal Cancer Stem Cells, Metastatic Colorectal Cancer Stem Cells, Serrated Colorectal Cancer Stem Cells 5) By Brain Cancer Stem Cells: Glioblastoma Stem Cells, Medulloblastoma Stem Cells, Astrocytoma Stem Cells, Oligodendroglioma Stem Cells, Ependymoma Stem Cells 6) By Leukemia Stem Cells: Acute Myeloid Leukemia Stem Cells, Chronic Myeloid Leukemia Stem Cells, Acute Lymphoblastic Leukemia Stem Cells, Chronic Lymphocytic Leukemia Stem Cells, Mixed Phenotype Acute Leukemia Stem Cells

What Is The Driver Of The Cancer Stem Cells Market?

The rising demand for personalized medicine is expected to propel the growth of the cancer stem cells market going forward. Personalized medicine refer to treatment approaches that are designed based on the genetic makeup, tumor biology, and individual response patterns of each patient to achieve higher effectiveness and lower side effects. The demand for personalized medicine is increasing due to the availability of genomic sequencing technologies, which are becoming more affordable and widely used in oncology research and clinical care. Personalized medicine targets cancer stem cells (CSCs) by tailoring treatments to the specific molecular and genetic characteristics of a patient’s tumor. Tumors are first analyzed for mutations, signaling pathways, and surface markers unique to their CSC population, allowing clinicians to select therapies that inhibit critical pathways. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rising demand for real-time risk assessment and mitigation solutions is driving the growth of the cancer stem cells industry.

Key Players In The Global Cancer Stem Cells Market

Major companies operating in the cancer stem cells market are MacroGenics Inc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Lonza Group AG, A. Menarini Industrie Farmaceutiche Riunite S.r.l., Bio-Techne Corporation, Zymeworks Inc., Kura Oncology Inc., GeneTex Inc., YZY Biopharma Co. Ltd., Abnova Taiwan Corporation, BioView Ltd., ScienCell Research Laboratories Inc., Boster Biological Technology Co. Ltd., AAT Bioquest Inc., Celprogen Inc., Actinium Pharmaceuticals Inc., OncoMed Pharmaceuticals Inc., Fate Therapeutics Inc., Verastem Oncology Inc.

Global Cancer Stem Cells Market Trends and Insights

Major companies operating in the cancer stem cells market are focusing on technological advancements such as pre-analytical immunomagnetic sorting systems to enhance cell enrichment for improved diagnostic accuracy. Pre-analytical immunomagnetic sorting systems refer to advanced tools that use magnetic particles coated with antibodies to isolate specific cancer stem cell populations from complex biological samples, improving sensitivity and reproducibility in downstream assays. For instance, in March 2024, STEMCELL Technologies, a Canada-based biotechnology company, launched the EasySep Human Bone Marrow CD138 Positive Selection Kit. The kit is the first hematopoietic cell enrichment product to receive FDA de novo classification as a Class II in vitro diagnostic device. It enriches CD138+ plasma cells from bone marrow samples to improve the detection of multiple myeloma-related abnormalities. The product ensures higher sensitivity, reproducibility, and diagnostic accuracy, ultimately improving patient outcomes in multiple myeloma care. The purpose of the product is to strengthen the pre-analytical stage of cancer diagnostics by delivering high-purity cell populations that allow more reliable downstream testing.

What Are Latest Mergers And Acquisitions In The Cancer Stem Cells Market?

In March 2023, Sona Nanotech Inc., a Canada-based nanotechnology and life sciences company, acquired Siva Therapeutics Inc. for $2 million. With this acquisition, Sona Nanotech aims to accelerate the development of Targeted Hyperthermia Therapy (THT) for colorectal cancer by integrating Siva’s photothermal treatment platform with its proprietary biocompatible gold nanorods, enabling minimally invasive procedures that stimulate immune response, shrink tumors, and improve drug delivery across multiple cancer types. Siva Therapeutics Inc. is a US-based biotechnology company specializing in photothermal cancer therapies using gold nanorod-based heat delivery systems.

Regional Outlook

North America was the largest region in the cancer stem cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Stem Cells Market?

The cancer stem cells market includes of revenues earned by entities by providing services such as biomarker identification, preclinical testing, clinical trial support, cell characterization and therapeutic development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Stem Cells Market Report 2026?

The cancer stem cells market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer stem cells industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.